Medincell Stock Plummets 13.5% Following Financial Report
The biotech company from Montpellier opens the session with heavy penalties. The stock collapses as the annual results show a significant deepening of net losses despite the increase in Uzedy royalties.
Medincell shares tumbled by 13.42% to €24.26 at the opening, down from €28.02 the previous day. The stock was the worst performer in the SBF 120, far ahead of the second-largest drop (Worldline, -3.88%), while the broader index hovered around equilibrium. The drop came after the financial results for 2025/2026 were revealed on June 16. Although Uzedy royalties jumped by 42% to €9.3 million, confirming a pivot towards recurring revenues, the net loss widened by 70% to €31.3 million, from €18.4 million a year earlier. The market was particularly concerned about the acceleration in R&D spending and the absence of non-recurring revenues that had supported the previous year. During this announcement, the company confirmed its target to commercially launch olanzapine LAI in the fourth quarter of 2026, a timeline that extends the monetization horizon of the pipeline.
Stock Breaks Through Moving Averages and Erases Part of the Year's Rally
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
The plunge pushed the stock price below its three moving averages in a single movement. At €24.26, the stock is now below the MM20 (€27.29, a gap of -11.10%), the MM50 (€25.86, -6.19%), and the MM200 (€25.84, -6.11%), a situation the stock has not seen since spring. The support threshold identified at €25.78 is decisively broken, with the price now settling €1.52 below this zone. The RSI at 57 does not yet reflect today's session and is expected to shift to lower levels after incorporating the bearish gap. Despite the shock, the annual performance remains positive at +56.62%, but the monthly decline has reached -11.40%, erasing part of the gains made since the start of the year. The next concrete milestone for investors: the commercial launch of olanzapine LAI scheduled for Q4 2026, identified as the main revenue catalyst in yesterday's publication.
SectorSanté · Biotechnologies · Vaccins et laboratoires de recherche›Biotechnologie
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: 9M 2025
Guidance from the release
We are pleased with the company’s growth and momentum.
Total income €14,1 million; Revenues €11,6 million (+35 %); UZEDY® royalties €4,2 million; Operating result €(6,6) million (improved 13 % year-over-year); Net result €(16 078) thousand; Cash and low-risk financial investments €53,5 million (incl. €49,8 million cash and €3,7 million low-risk investments); Net financial debt €17 629 thousand; NDA for Olanzapine LAI submitted to FDA on December 9, 2025; AbbVie partnership advancing with regulatory package expected in 2026.
Risks mentioned
Foreign exchange risk: weakness of USD vs EUR impacted revenues and generated ~€1 million FX losses
Dependency on partner commercialization (Teva) for UZEDY® royalties and sales forecasts
Regulatory risk: approvals (e.g., Olanzapine LAI) and acceptance for review uncertain
Financial volatility linked to fair value revaluation of EIB BSA warrants (non-cash €6,8 million impact)
Opportunities identified
Olanzapine LAI: NDA submitted and potential launch could be a major growth catalyst
UZEDY®: upward revision of 2025 net sales forecast by Teva (from $160 million to $190-200 million)
AbbVie partnership: first program advancing toward first-in-human trials (regulatory package expected 2026)
Gates Foundation financing: new $3 million envelope to advance mdc-STM malaria program
Expanded geographic approvals (Canada, South Korea) supporting broader commercialization
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
